Document Detail


The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer.
MedLine Citation:
PMID:  22184496     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The adoption of a chemotherapeutic regimen in oncologic practice is a function of both its clinical and its economic impacts on cancer management. For breast cancer, U.S. Oncology trial 9735 reported significant improvements in disease-free and overall survival favoring adjuvant tc (docetaxel 75 mg/m(2) and cyclophosphamide 600 mg/m(2) every 3 weeks for 4 cycles) compared with ac (doxorubicin 60 mg/ m(2) and cyclophosphamide 600 mg/m(2) every 3 weeks for 4 cycles). We carried out an economic evaluation to examine the cost-utility of adjuvant tc relative to ac, in terms of cost per quality-adjusted life year (qaly) gained, given the improved breast cancer outcomes and higher costs associated with the tc regimen.
METHODS: A Markov model was developed to calculate the cumulative costs and qalys gained over a 10-year horizon for hypothetical cohorts of women with breast cancer treated with ac or with tc. Event rates, costs, and utilities were derived from the literature and local resources. Efficacy and adverse events were based on results reported from U.S. Oncology trial 9735. The model takes a third-party direct payer perspective and reports its results in 2008 Canadian dollars. Costs and benefits were both discounted at 3%.
RESULTS: At a 10-year horizon, tc was associated with $3,960 incremental costs and a 0.24 qaly gain compared with ac, for a favorable cost-utility of $16,753 per qaly gained. Results were robust to model assumptions and input parameters.
CONCLUSIONS: Relative to ac, tc is a cost-effective adjuvant chemotherapy regimen, with a cost-effectiveness ratio well below commonly applied thresholds.
Authors:
T Younis; D Rayson; C Skedgel
Related Documents :
22045176 - Minimally invasive retroperitoneal lymph node dissection for testicular cancer.
22182766 - French recommendations for endometrial cancer 2010: clinical use and questions still de...
21893496 - Brush-based cytology screening in the tonsils and cervix: there is a difference!
21702036 - Time since first sexual intercourse and the risk of cervical cancer.
8807476 - Distribution of pedal burns by source and depth.
19654946 - Clinical analysis of patients who survived for less than 3 months after brain metastate...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current oncology (Toronto, Ont.)     Volume:  18     ISSN:  1198-0052     ISO Abbreviation:  Curr Oncol     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-12-20     Completed Date:  2012-08-23     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  9502503     Medline TA:  Curr Oncol     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  e288-96     Citation Subset:  -    
Affiliation:
Department of Medicine, Dalhousie University, QEII Health Sciences Centre, Halifax, NS.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Inter-rater reliability between musculoskeletal radiologists and orthopedic surgeons on computed tom...
Next Document:  Patterns of presentation, referral, and treatment of hepatocellular carcinoma in a pre-sorafenib era...